Updated prognostic factors in localized NSCLC

S Garinet, P Wang, A Mansuet-Lupo, L Fournel… - Cancers, 2022 - mdpi.com
Simple Summary In resected lung cancer, adjuvant and neoadjuvant chemotherapy
following surgery are currently mainly based on TNM classification. With the validation and …

Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives

LA Godoy, J Chen, W Ma, J Lally, KA Toomey… - Biomarker …, 2023 - Springer
Over the past decade, targeted therapy for oncogene-driven NSCLC and immune
checkpoint inhibitors for non-oncogene-driven NSCLC, respectively, have greatly improved …

[HTML][HTML] Lymph node micrometastasis in non–small cell lung cancer

J Sun, S Wu, Z Jin, S Ren, WC Cho, C Zhu… - Biomedicine & …, 2022 - Elsevier
Lung cancer has some of the highest morbidity and mortality rates of all cancers, and an
important risk factor for mortality in patients with lung cancer is tumor metastasis. Even if a …

Could tumor spread through air spaces benefit from adjuvant chemotherapy in stage I lung adenocarcinoma? A multi-institutional study

D Chen, X Wang, F Zhang, R Han… - Therapeutic …, 2020 - journals.sagepub.com
Background: The benefit of adjuvant chemotherapy (ACT) remains unknown for patients with
stage I lung adenocarcinoma (ADC) with spread through air spaces (STAS). This study …

The impact of adjuvant EGFR-TKIs and 14-gene molecular assay on stage I non–small cell lung cancer with sensitive EGFR mutations

Y Jiang, Y Lin, W Fu, Q He, H Liang, R Zhong… - …, 2023 - thelancet.com
Background Currently, the role of EGFR-TKIs as adjuvant therapy for stage I, especially IA
NSCLC, after surgical resection remains unclear. We aimed to compare the effect of …

[HTML][HTML] EFHD2 contributes to non-small cell lung cancer cisplatin resistance by the activation of NOX4-ROS-ABCC1 axis

CC Fan, ST Tsai, CY Lin, LC Chang, JC Yang… - Redox Biology, 2020 - Elsevier
Recurrence and metastasis remain the major cause of cancer mortality. Even for early-stage
lung cancer, adjuvant chemotherapy yields merely slight increase to patient survival. EF …

A nomogram combined radiomics and clinical features as imaging biomarkers for prediction of visceral pleural invasion in lung adenocarcinoma

X Zha, Y Liu, X Ping, J Bao, Q Wu, S Hu, C Hu - Frontiers in Oncology, 2022 - frontiersin.org
Objectives To develop and validate a nomogram model based on radiomics features for
preoperative prediction of visceral pleural invasion (VPI) in patients with lung …

Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis

R Zhong, R Gao, W Fu, C Li, Z Huo, Y Gao, Y Lu, F Li… - BMC medicine, 2023 - Springer
Background The sensitivity and specificity of minimal residual disease detected by
circulating tumor DNA profiling (ctDNA MRD) in lung cancer, with particular attention to the …

Stratification of patients with stage IB NSCLC based on the 8th edition of the American joint committee on cancer (AJCC) staging manual

LL Wu, X Liu, WM Jiang, W Huang, P Lin… - Frontiers in …, 2020 - frontiersin.org
Objective: To assess the postoperative prognosis of patients with stage IB non-small cell
lung cancer (NSCLC), using a prognostic model (PM). Methods: Patients with stage IB of …

A Six‐Gene Signature Predicts Survival of Adenocarcinoma Type of Non‐Small‐Cell Lung Cancer Patients: A Comprehensive Study Based on Integrated Analysis …

H Xie, C Xie - BioMed Research International, 2019 - Wiley Online Library
Background and Goals. To identify a multigene signature model for prognosis of non‐small‐
cell lung cancer (NSCLC) patients, we first found 2146 consensus differentially expressed …